Ritonavir (BioDeep_00000397570)

Main id: BioDeep_00000001513

 

natural product


代谢物信息卡片


Ritonavir

化学式: C37H48N6O5S2 (720.3127)
中文名称: 利托那韦
谱图信息: 最多检出来源 Homo sapiens(not specific) 8.33%

分子结构信息

SMILES: c(c1)cc(CC(NC(=O)C(C(C)C)NC(=O)N(Cc(n4)csc4C(C)C)C)CC(C(NC(=O)OCc(c3)scn3)Cc(c2)cccc2)O)cc1
InChI: InChI=1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)/t28-,31-,32-,33-/m0/s1

描述信息

J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals > J05AE - Protease inhibitors
D004791 - Enzyme Inhibitors > D065607 - Cytochrome P-450 Enzyme Inhibitors > D065692 - Cytochrome P-450 CYP3A Inhibitors
COVID info from Guide to PHARMACOLOGY, DrugBank, clinicaltrial, clinicaltrials, clinical trial, clinical trials
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D000084762 - Viral Protease Inhibitors
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents
C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C97366 - HIV Protease Inhibitor
C254 - Anti-Infective Agent > C281 - Antiviral Agent > C1660 - Anti-HIV Agent
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS
CONFIDENCE standard compound; INTERNAL_ID 2192
CONFIDENCE standard compound; EAWAG_UCHEM_ID 2580
EAWAG_UCHEM_ID 2580; CONFIDENCE standard compound

同义名列表

2 个代谢物同义名

Ritonavir; Ritonavir



数据库引用编号

56 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表
Cytoplasm 8 ALB, CASP3, CST3, CYP2B6, CYP2C19, CYP2C9, EGFR, SRY
Peripheral membrane protein 1 CYP2B6
Endosome membrane 1 EGFR
Endoplasmic reticulum membrane 5 CYP1A2, CYP2B6, CYP2C19, CYP2C9, EGFR
Nucleus 4 ALB, CASP3, EGFR, SRY
cytosol 2 ALB, CASP3
centrosome 1 ALB
nucleoplasm 2 CASP3, SRY
Cell membrane 4 CD8A, EGFR, SLCO1B1, TNF
ruffle membrane 1 EGFR
Early endosome membrane 1 EGFR
Multi-pass membrane protein 1 SLCO1B1
cell junction 1 EGFR
cell surface 4 ADIPOQ, CD38, EGFR, TNF
glutamatergic synapse 2 CASP3, EGFR
Golgi apparatus 2 ALB, CST3
Golgi membrane 2 EGFR, INS
neuronal cell body 2 CASP3, TNF
endosome 1 EGFR
plasma membrane 9 CD38, CD8A, CST3, CYP2C19, CYP2C9, EGFR, IFNLR1, SLCO1B1, TNF
Membrane 4 CD38, EGFR, IFNLR1, SLCO1B1
apical plasma membrane 1 EGFR
basolateral plasma membrane 3 CD38, EGFR, SLCO1B1
extracellular exosome 3 ALB, CD38, CST3
endoplasmic reticulum 3 ADIPOQ, ALB, CST3
extracellular space 10 ADIPOQ, ALB, CCL2, CRP, CST3, CXCL8, EGFR, IL6, INS, TNF
perinuclear region of cytoplasm 1 EGFR
protein-containing complex 2 ALB, EGFR
intracellular membrane-bounded organelle 4 CYP1A2, CYP2B6, CYP2C19, CYP2C9
Microsome membrane 3 CYP1A2, CYP2B6, CYP2C9
postsynaptic density 1 CASP3
Single-pass type I membrane protein 3 CD8A, EGFR, IFNLR1
Secreted 8 ADIPOQ, ALB, CCL2, CRP, CST3, CXCL8, IL6, INS
extracellular region 10 ADIPOQ, ALB, CCL2, CD8A, CRP, CST3, CXCL8, IL6, INS, TNF
[Isoform 2]: Secreted 1 CD8A
anchoring junction 1 ALB
nuclear membrane 2 CD38, EGFR
external side of plasma membrane 2 CD8A, TNF
recycling endosome 1 TNF
Single-pass type II membrane protein 2 CD38, TNF
vesicle 1 CST3
Membrane raft 2 EGFR, TNF
focal adhesion 1 EGFR
collagen trimer 1 ADIPOQ
intracellular vesicle 1 EGFR
collagen-containing extracellular matrix 1 ADIPOQ
nuclear speck 1 SRY
receptor complex 2 CD8A, EGFR
ciliary basal body 1 ALB
chromatin 1 SRY
phagocytic cup 1 TNF
centriole 1 ALB
spindle pole 1 ALB
blood microparticle 1 ALB
Basolateral cell membrane 1 SLCO1B1
endosome lumen 1 INS
Nucleus speckle 1 SRY
basal plasma membrane 2 EGFR, SLCO1B1
synaptic membrane 1 EGFR
plasma membrane raft 1 CD8A
ficolin-1-rich granule lumen 1 CST3
secretory granule lumen 1 INS
Golgi lumen 1 INS
endoplasmic reticulum lumen 4 ALB, CST3, IL6, INS
platelet alpha granule lumen 1 ALB
tertiary granule lumen 1 CST3
transport vesicle 1 INS
Endoplasmic reticulum-Golgi intermediate compartment membrane 1 INS
clathrin-coated endocytic vesicle membrane 1 EGFR
Basal cell membrane 1 SLCO1B1
death-inducing signaling complex 1 CASP3
[Isoform 1]: Cell membrane 1 CD8A
multivesicular body, internal vesicle lumen 1 EGFR
Shc-EGFR complex 1 EGFR
[Tumor necrosis factor, soluble form]: Secreted 1 TNF
T cell receptor complex 1 CD8A
interleukin-6 receptor complex 1 IL6
ciliary transition fiber 1 ALB
interleukin-28 receptor complex 1 IFNLR1
[C-domain 2]: Secreted 1 TNF
[Tumor necrosis factor, membrane form]: Membrane 1 TNF
[C-domain 1]: Secreted 1 TNF


文献列表

  • Chung-Kai Sun, Yen-Ying Kung, Wan-Hsin Lee, Lie-Chwen Lin, Muh-Hwa Yang, Tung-Hu Tsai. Pharmacokinetic analysis of antiviral drug ritonavir across the blood-brain barrier and its interaction with Scutellaria baicalensis using multisite microdialysis in rats. Journal of pharmaceutical and biomedical analysis. 2024 Aug; 245(?):116162. doi: 10.1016/j.jpba.2024.116162. [PMID: 38678857]
  • Heta H Desai, Abu T M Serajuddin. Development of lipid-based SEDDS using digestion products of long-chain triglyceride for high drug solubility: Formulation and dispersion testing. International journal of pharmaceutics. 2024 Apr; 654(?):123953. doi: 10.1016/j.ijpharm.2024.123953. [PMID: 38417725]
  • Hui Yang, Xin Yu, Wenjing Hou, Xiangduan Liu, Jiaojiao Chen, Ying Zhang, Ying Wang, Ying Zhu, Qing Qian, Kuifen Ma, Zhuoling An. Effectiveness and safety of nirmatrelvir-ritonavir in kidney transplant recipients with severe kidney dysfunction infected with COVID-19. Antimicrobial agents and chemotherapy. 2024 Mar; 68(3):e0138423. doi: 10.1128/aac.01384-23. [PMID: 38289075]
  • Bei Zheng, Qinqin Zhao, Wenjuan Yang, Pinpin Feng, Chuanwei Xin, Yin Ying, Bo Yang, Bing Han, Jun Zhu, Meiling Zhang, Gonghua Li. Small-molecule antiviral treatments for COVID-19: A systematic review and network meta-analysis. International journal of antimicrobial agents. 2024 Mar; 63(3):107096. doi: 10.1016/j.ijantimicag.2024.107096. [PMID: 38244811]
  • Chloe Orkin, Jean-Michel Molina, Pedro Cahn, Johannes Lombaard, Khuanchai Supparatpinyo, Sushma Kumar, Havilland Campbell, Hong Wan, Valerie Teal, Zhi Jin Xu, Ernest Asante-Appiah, Peter Sklar, Hedy Teppler, Rima Lahoulou. Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials. The lancet. HIV. 2024 Feb; 11(2):e75-e85. doi: 10.1016/s2352-3018(23)00258-8. [PMID: 38141637]
  • Jianchao Xu, Jinzhong Song, Ziyu Xie, Jie Yang, Di Wu, Fengshuang Liu, Yinuo Zhao, Hongmin Zang, Yubin Zhao. Impact of Paxlovid on in-hospital outcomes and post-COVID-19 condition in adult patients infected with SARS-CoV-2 Omicron variant: A non-randomized controlled clinical trial. Medicine. 2023 Dec; 102(51):e36714. doi: 10.1097/md.0000000000036714. [PMID: 38134107]
  • Abdurezak Ahmed Abdela, Helen Yifter, Ahmed Reja, Aster Shewaamare, Ighovwerha Ofotokun, Wondwossen Amogne Degu. Prevalence and risk factors of metabolic syndrome in Ethiopia: describing an emerging outbreak in HIV clinics of the sub-Saharan Africa - a cross-sectional study. BMJ open. 2023 12; 13(12):e069637. doi: 10.1136/bmjopen-2022-069637. [PMID: 38070936]
  • Zhuo Yu, Yanxi Zheng, Bowu Chen, Jia Lv, Xiaojun Zhu, Binyi Shang, Yuping Xv, Ru Tao, Yanbing Yang, Jun Cong, Dan Li, Huan Wu, Wenchao Qv, Xiyi Zhang, Chengbin Xv, Hai Feng, Weian Yuan, Yueqiu Gao. Efficacy and safety of Huashi Baidu granule plus Nirmatrelvir-Ritonavir combination therapy in patients with high-risk factors infected with Omicron (B.1.1.529): A multi-arm single-center, open-label, randomized controlled trial. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2023 Nov; 120(?):155025. doi: 10.1016/j.phymed.2023.155025. [PMID: 37639813]
  • Ioannis I Andreadis, Arne Schulzen, Julian Quodbach, Christel A S Bergström. Exploring the use of modified in vitro digestion assays for the evaluation of ritonavir loaded solid lipid-based formulations. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2023 Oct; 189(?):106524. doi: 10.1016/j.ejps.2023.106524. [PMID: 37433412]
  • Srinivas Reddy Jitta, Salwa, Navya Ajitkumar Bhaskaran, Shirleen Miriam Marques, Lalit Kumar, Sri Pragnya Cheruku, Vanishree Rao, Pravesh Sharma, Onkar Prakash Kulkarni. Enhanced tissue distribution of ritonavir-loaded nanostructured lipid carriers-recommending its dose reduction. Drug delivery and translational research. 2023 Jul; ?(?):. doi: 10.1007/s13346-023-01386-9. [PMID: 37402943]
  • V Krishnaraju, Y Alghazwani, S Durgaramani, Y I Asiri, K Prabahar, K Kalpana, V Rajalakshimi, A K Noohu, P Premalatha, S A Sirajudeen, V Kumar, V Vinoth Prabhu. Beneficial effects of Naringin against lopinavir/ ritonavir-induced hyperlipidemia and reproductive toxicity in male albino rats. European review for medical and pharmacological sciences. 2023 May; 27(9):4221-4231. doi: 10.26355/eurrev_202305_32332. [PMID: 37203848]
  • Malinda Salim, Gisela Ramirez, Andrew J Clulow, Adrian Hawley, Ben J Boyd. Implications of the Digestion of Milk-Based Formulations for the Solubilization of Lopinavir/Ritonavir in a Combination Therapy. Molecular pharmaceutics. 2023 Apr; 20(4):2256-2265. doi: 10.1021/acs.molpharmaceut.3c00072. [PMID: 36919249]
  • Zhujun Cao, Weiyi Gao, Hong Bao, Haiyan Feng, Shuya Mei, Peizhan Chen, Yueqiu Gao, Zhilei Cui, Qin Zhang, Xianmin Meng, Honglian Gui, Weijing Wang, Yimei Jiang, Zijia Song, Yiqing Shi, Jing Sun, Yifei Zhang, Qing Xie, Yiping Xu, Guang Ning, Yuan Gao, Ren Zhao. VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19. The New England journal of medicine. 2023 02; 388(5):406-417. doi: 10.1056/nejmoa2208822. [PMID: 36577095]
  • Wantin Sribenjalux, Tharatorn Nuntawit, Atibordee Meesing, Ploenchan Chetchotisakd. Virological outcomes and metabolic effects after switching from ritonavir-boosted protease inhibitors to a dolutegravir-based regimen in virologically suppressed patients living with HIV. International journal of STD & AIDS. 2023 02; 34(2):98-107. doi: 10.1177/09564624221137972. [PMID: 36378013]
  • Wen Wen, Chen Chen, Jiake Tang, Chunyi Wang, Mengyun Zhou, Yongran Cheng, Xiang Zhou, Qi Wu, Xingwei Zhang, Zhanhui Feng, Mingwei Wang, Qin Mao. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis. Annals of medicine. 2022 12; 54(1):516-523. doi: 10.1080/07853890.2022.2034936. [PMID: 35118917]
  • He Xu, Ge Liu, Jixing Gong, Ying Zhang, Shanshan Gu, Zhongjun Wan, Pengcheng Yang, Yage Nie, Yinghan Wang, Zhan-Peng Huang, Guanzheng Luo, Zhongyan Chen, Donghui Zhang, Nan Cao. Investigating and Resolving Cardiotoxicity Induced by COVID-19 Treatments using Human Pluripotent Stem Cell-Derived Cardiomyocytes and Engineered Heart Tissues. Advanced science (Weinheim, Baden-Wurttemberg, Germany). 2022 10; 9(30):e2203388. doi: 10.1002/advs.202203388. [PMID: 36055796]
  • Piyush Kashyap, Mamta Thakur, Nidhi Singh, Deep Shikha, Shiv Kumar, Poonam Baniwal, Yogender Singh Yadav, Minaxi Sharma, Kandi Sridhar, Baskaran Stephen Inbaraj. In Silico Evaluation of Natural Flavonoids as a Potential Inhibitor of Coronavirus Disease. Molecules (Basel, Switzerland). 2022 Sep; 27(19):. doi: 10.3390/molecules27196374. [PMID: 36234910]
  • Georgia-Ioanna Nora, Ramakrishnan Venkatasubramanian, Sophie Strindberg, Scheyla Daniela Siqueira-Jørgensen, Livia Pagano, Francis S Romanski, Nitin K Swarnakar, Thomas Rades, Anette Müllertz. Combining lipid based drug delivery and amorphous solid dispersions for improved oral drug absorption of a poorly water-soluble drug. Journal of controlled release : official journal of the Controlled Release Society. 2022 09; 349(?):206-212. doi: 10.1016/j.jconrel.2022.06.057. [PMID: 35787914]
  • Bin Su, Cheng Yao, Qing-Xia Zhao, Wei-Ping Cai, Min Wang, Hong-Zhou Lu, Ting-Ting Mu, Yuan-Yuan Chen, Li Liu, Hui Wang, Yun He, Yu-Huang Zheng, Ling-Hua Li, Jin-Feng Chen, Jian-Hua Yu, Biao Zhu, Min Zhao, Yong-Tao Sun, Wen-Hui Lun, Yi-Hang Zhang, Hu Wang, Wei Xia, Li-Jun Sun, Li-Li Dai, Tai-Yi Jiang, Mei-Xia Wang, Qing-Shan Zheng, Hai-Yan Peng, Yao Wang, Min Hu, Xia Liu, Rong-Jian Lu, Jian-Hua Hu, Cheng-Chen Sun, Hui Xing, Yi-Ming Shao, Dong Xie, Tong Zhang, Fu-Jie Zhang, Hao Wu. Long-acting HIV fusion inhibitor albuvirtide combined with ritonavir-boosted lopinavir for HIV-1-infected patients after failing the first-line antiretroviral therapy: 48-week randomized, controlled, phase 3 non-inferiority TALENT study. The Journal of infection. 2022 09; 85(3):334-363. doi: 10.1016/j.jinf.2022.05.034. [PMID: 35659547]
  • J R Azanza, J Mensa, J González Del Castillo, M Linares Rufo, J M Molero, N Madero Valle, J Barberán. Interactions listed in the Paxlovid fact sheet, classified according to risks, pharmacological groups, and consequences. Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia. 2022 Aug; 35(4):357-361. doi: 10.37201/req/054.2022. [PMID: 35822605]
  • Janice Hopkins Tanne. Covid-19: FDA authorises pharmacists to prescribe Paxlovid. BMJ (Clinical research ed.). 2022 07; 378(?):o1695. doi: 10.1136/bmj.o1695. [PMID: 35803606]
  • Xenia Bacinschi, Gabriel Cristian Popescu, Anca Zgura, Laurentia Gales, Anghel Rodica, Adriana Mercan, Dragos Serban, Bogdan Haineala, Letitia Toma, Laura Iliescu. A Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, with or without Ribavirin, in 587 Patients with Chronic Hepatitis C at the Fundeni Clinical Institute, Bucharest, Romania. Medical science monitor : international medical journal of experimental and clinical research. 2022 Jul; 28(?):e936706. doi: 10.12659/msm.936706. [PMID: 35787600]
  • Sumit Arora, Amita Pansari, Peter J Kilford, Masoud Jamei, David B Turner, Iain Gardner. A Mechanistic Absorption and Disposition Model of Ritonavir to Predict Exposure and Drug-Drug Interaction Potential of CYP3A4/5 and CYP2D6 Substrates. European journal of drug metabolism and pharmacokinetics. 2022 Jul; 47(4):483-495. doi: 10.1007/s13318-022-00765-w. [PMID: 35486324]
  • Mehdi Hassaniazad, Hossein Farshidi, Abdollah Gharibzadeh, Ali Bazram, Elham Khalili, Afsaneh Noormandi, Mohammad Fathalipour. Efficacy and safety of favipiravir plus interferon-beta versus lopinavir/ritonavir plus interferon-beta in moderately ill patients with COVID-19: A randomized clinical trial. Journal of medical virology. 2022 Jul; 94(7):3184-3191. doi: 10.1002/jmv.27724. [PMID: 35292989]
  • Maarten van Eijk, Huixin Yu, Emilia Sawicki, Vincent A de Weger, Bastiaan Nuijen, Thomas P C Dorlo, Jos H Beijnen, Alwin D R Huitema. Development of a population pharmacokinetic/pharmacodynamic model for various oral paclitaxel formulations co-administered with ritonavir and thrombospondin-1 based on data from early phase clinical studies. Cancer chemotherapy and pharmacology. 2022 Jul; 90(1):71-82. doi: 10.1007/s00280-022-04445-z. [PMID: 35799067]
  • Vishal C Gurumukhi, Sanjaykumar B Bari. Development of ritonavir-loaded nanostructured lipid carriers employing quality by design (QbD) as a tool: characterizations, permeability, and bioavailability studies. Drug delivery and translational research. 2022 07; 12(7):1753-1773. doi: 10.1007/s13346-021-01083-5. [PMID: 34671949]
  • A Dubois, A Féral, J-B Pain, J Michot, D Fansi Ndengoue, A Benomar, E Clou, I Debrix. [Treatments for SARS-CoV-2 infection: A retrospective study of drug-drug interactions and safety]. Annales pharmaceutiques francaises. 2022 Jul; 80(4):531-542. doi: 10.1016/j.pharma.2021.11.001. [PMID: 34748737]
  • Talha Burki. The future of Paxlovid for COVID-19. The Lancet. Respiratory medicine. 2022 07; 10(7):e68. doi: 10.1016/s2213-2600(22)00192-8. [PMID: 35623373]
  • Ravi Shankar P Singh, Sima S Toussi, Frances Hackman, Phylinda L Chan, Rohit Rao, Richard Allen, Lien Van Eyck, Sylvester Pawlak, Eugene P Kadar, Frances Clark, Haihong Shi, Annaliesa S Anderson, Michael Binks, Sandeep Menon, Gianluca Nucci, Arthur Bergman. Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir. Clinical pharmacology and therapeutics. 2022 Jul; 112(1):101-111. doi: 10.1002/cpt.2603. [PMID: 35388471]
  • José L Blanco, Jhon Rojas, Elisa de Lazzari, Alexy Inciarte, Mar Subirana, Pilar Callau, María Martinez-Rebollar, Montserrat Laguno, Josep Mallolas, Lorena de la Mora, Berta Torres, Ana Gonzalez-Cordón, Esteban Martinez. Simplification from tenofovir disoproxil fumarate plus lamivudine or emtricitabine plus ritonavir-boosted protease inhibitor to ritonavir-boosted atazanavir plus lamivudine in virologically suppressed HIV-infected adults with osteopenia: a pilot study. The Journal of antimicrobial chemotherapy. 2022 06; 77(7):1974-1979. doi: 10.1093/jac/dkac137. [PMID: 35512339]
  • Rita Rubin. From Positive to Negative to Positive Again-The Mystery of Why COVID-19 Rebounds in Some Patients Who Take Paxlovid. JAMA. 2022 06; 327(24):2380-2382. doi: 10.1001/jama.2022.9925. [PMID: 35675094]
  • Rohini Kharwade, Sachin More, Elizabeth Suresh, Amol Warokar, Nilesh Mahajan, Ujwala Mahajan. Improvement in Bioavailability and Pharmacokinetic Characteristics of Efavirenz with Booster Dose of Ritonavir in PEGylated PAMAM G4 Dendrimers. AAPS PharmSciTech. 2022 Jun; 23(6):177. doi: 10.1208/s12249-022-02315-8. [PMID: 35750994]
  • Deborah E Malden, Vennis Hong, Bruno J Lewin, Bradley K Ackerson, Marc Lipsitch, Joseph A Lewnard, Sara Y Tartof. Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment - California, December 2021-May 2022. MMWR. Morbidity and mortality weekly report. 2022 Jun; 71(25):830-833. doi: 10.15585/mmwr.mm7125e2. [PMID: 35737591]
  • Amedeo De Nicolò, Andrea Calcagno, Ilaria Motta, Elisa De Vivo, Antonio D'Avolio, Giovanni Di Perri, Lubbe Wiesner, Isma-Eel Ebrahim, Gary Maartens, Catherine Orrell, Helen McIlleron. The Effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within Peripheral Blood Mononuclear Cells: a Dose Escalation Study. Antimicrobial agents and chemotherapy. 2022 06; 66(6):e0013622. doi: 10.1128/aac.00136-22. [PMID: 35583344]
  • NULL. COVID-19 update: NIH recommends against ivermectin. The Medical letter on drugs and therapeutics. 2022 06; 64(1652):95-96. doi: NULL. [PMID: 35657909]
  • Bożena Czech, Agnieszka Krzyszczak, Anna Boguszewska-Czubara, Grzegorz Opielak, Izabela Jośko, Mirabbos Hojamberdiev. Revealing the toxicity of lopinavir- and ritonavir-containing water and wastewater treated by photo-induced processes to Danio rerio and Allivibrio fischeri. The Science of the total environment. 2022 Jun; 824(?):153967. doi: 10.1016/j.scitotenv.2022.153967. [PMID: 35182634]
  • David Phizackerley. Three more points about Paxlovid for covid-19. BMJ (Clinical research ed.). 2022 06; 377(?):o1397. doi: 10.1136/bmj.o1397. [PMID: 35672048]
  • Sibel Ucpinar, Borje Darpo, Ann Neale, Philip Nunn, Jin Shu, Katherine A Chu, Marianne Kavanagh, Hongqi Xue, Pasit Phiasivongsa, Dolca Thomas, Patrick F Smith. A thorough QTc study to evaluate the effects of oral rilzabrutinib administered alone and with ritonavir in healthy subjects. Clinical and translational science. 2022 Jun; 15(6):1507-1518. doi: 10.1111/cts.13271. [PMID: 35301810]
  • Kristen E Lindauer, Ashlee G Hamel. Case Report: Nirmatrelvir/Ritonavir and Tacrolimus in a Kidney Transplant Recipient With COVID-19. American family physician. 2022 06; 105(6):569-570. doi: NULL. [PMID: 35704835]
  • J Reina, C Iglesias. [Nirmatrelvir plus ritonavir (Paxlovid) a potent SARS-CoV-2 3CLpro protease inhibitor combination]. Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia. 2022 Jun; 35(3):236-240. doi: 10.37201/req/002.2022. [PMID: 35183067]
  • Nicholas I Paton, Joseph Musaazi, Cissy Kityo, Stephen Walimbwa, Anne Hoppe, Apolo Balyegisawa, Jesca Asienzo, Arvind Kaimal, Grace Mirembe, Abbas Lugemwa, Gilbert Ategeka, Margaret Borok, Henry Mugerwa, Abraham Siika, Eva Laker A Odongpiny, Barbara Castelnuovo, Agnes Kiragga, Andrew Kambugu. Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial. The lancet. HIV. 2022 06; 9(6):e381-e393. doi: 10.1016/s2352-3018(22)00092-3. [PMID: 35460601]
  • Caroline S Foo, Rana Abdelnabi, Suzanne J F Kaptein, Xin Zhang, Sebastiaan Ter Horst, Raf Mols, Leen Delang, Joana Rocha-Pereira, Lotte Coelmont, Pieter Leyssen, Kai Dallmeier, Valentijn Vergote, Elisabeth Heylen, Laura Vangeel, Arnab K Chatterjee, Pieter P Annaert, Patrick F Augustijns, Steven De Jonghe, Dirk Jochmans, Mieke Gouwy, Seppe Cambier, Jennifer Vandooren, Paul Proost, Christine van Laer, Birgit Weynand, Johan Neyts. HIV protease inhibitors Nelfinavir and Lopinavir/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect. Antiviral research. 2022 06; 202(?):105311. doi: 10.1016/j.antiviral.2022.105311. [PMID: 35390430]
  • Cihan Yurdaydin, Onur Keskin, Esra Yurdcu, Aysun Çalişkan, Soner Önem, Fatih Karakaya, Çağdaş Kalkan, Ersin Karatayli, Senem Karatayli, Ingrid Choong, David Apelian, Christopher Koh, Theo Heller, Ramazan Idilman, A Mithat Bozdayi, Jeffrey S Glenn. A phase 2 dose-finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis. Hepatology (Baltimore, Md.). 2022 06; 75(6):1551-1565. doi: 10.1002/hep.32259. [PMID: 34860418]
  • Ruxandra-Cristina Marin, Adrian Streinu-Cercel, Lavinia Cristina Moleriu, Simona Gabriela Bungau. Analysis of virological response to therapy and resistance profile in treatment-experienced and naive HIV-1 infected Romanian patients receiving regimens containing darunavir boosted with ritonavir or cobicistat. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2022 Jun; 150(?):113077. doi: 10.1016/j.biopha.2022.113077. [PMID: 35658217]
  • Athanasios Vassilopoulos, Eleftherios Mylonakis. In patients with COVID-19 at risk for severe disease, nirmatrelvir + ritonavir reduced hospitalization or death. Annals of internal medicine. 2022 06; 175(6):JC63. doi: 10.7326/j22-0038. [PMID: 35667068]
  • Eunjin Hong, Lisa M Almond, Peter S Chung, Adupa P Rao, Paul M Beringer. Physiologically-Based Pharmacokinetic-Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor-Tezacaftor-Ivacaftor With Nirmatrelvir-Ritonavir for the Treatment of COVID-19. Clinical pharmacology and therapeutics. 2022 06; 111(6):1324-1333. doi: 10.1002/cpt.2585. [PMID: 35292968]
  • Ferenc A Bartha, Nóra Juhász, Sadegh Marzban, Renji Han, Gergely Röst. In Silico Evaluation of Paxlovid's Pharmacometrics for SARS-CoV-2: A Multiscale Approach. Viruses. 2022 05; 14(5):. doi: 10.3390/v14051103. [PMID: 35632843]
  • Anne Caufriez, Andrés Tabernilla, Raf Van Campenhout, Axelle Cooreman, Kaat Leroy, Julen Sanz Serrano, Prashant Kadam, Bruna Dos Santos Rodrigues, Arthur Lamouroux, Steven Ballet, Mathieu Vinken. Effects of Drugs Formerly Suggested for COVID-19 Repurposing on Pannexin1 Channels. International journal of molecular sciences. 2022 May; 23(10):. doi: 10.3390/ijms23105664. [PMID: 35628472]
  • Osman Moneer, Garrison Daly, Joshua J Skydel, Kate Nyhan, Peter Lurie, Joseph S Ross, Joshua D Wallach. Agreement of treatment effects from observational studies and randomized controlled trials evaluating hydroxychloroquine, lopinavir-ritonavir, or dexamethasone for covid-19: meta-epidemiological study. BMJ (Clinical research ed.). 2022 05; 377(?):e069400. doi: 10.1136/bmj-2021-069400. [PMID: 35537738]
  • Mark H Ebell. Nirmatrelvir/Ritonavir Reduces Risk of Hospitalization in At-Risk Outpatients. American family physician. 2022 05; 105(5):Online. doi: NULL. [PMID: 35559642]
  • Catia Marzolini, Daniel R Kuritzkes, Fiona Marra, Alison Boyle, Sara Gibbons, Charles Flexner, Anton Pozniak, Marta Boffito, Laura Waters, David Burger, David Back, Saye Khoo. Prescribing Nirmatrelvir-Ritonavir: How to Recognize and Manage Drug-Drug Interactions. Annals of internal medicine. 2022 05; 175(5):744-746. doi: 10.7326/m22-0281. [PMID: 35226530]
  • Alasdair MacGowan, Fergus Hamilton, Mark Bayliss, Liam Read, Marie Attwood, Alan Noel, Maha Albur, Sally Grier, Anna Morley, David Arnold, Nicholas Maskell. Letter to the Editor: Pharmacokinetics of Lopinavir/Ritonavir in Hospitalized Patients with COVID-19 Not Requiring Critical Care. Microbial drug resistance (Larchmont, N.Y.). 2022 05; 28(5):611-612. doi: 10.1089/mdr.2021.0259. [PMID: 35099290]
  • Carlos K H Wong, Marshall C H Low, Ashley C Y Kwok, Angel Y C Lui, Kristy T K Lau, Ivan C H Au, Xi Xiong, Matthew S H Chung, Mike Y W Kwan, Eric H Y Lau, Benjamin J Cowling. Slower Recovery with Early Lopinavir/Ritonavir use in Pediatric COVID-19 Patients: A Retrospective Observational Study. Paediatric drugs. 2022 May; 24(3):269-280. doi: 10.1007/s40272-022-00500-7. [PMID: 35428969]
  • Keiko Minami, Makoto Kataoka, Toshihide Takagi, Tomohiro Asai, Naoto Oku, Shinji Yamashita. Liposomal Formulation for Oral Delivery of Cyclosporine A: Usefulness as a Semisolid-Dispersion System. Pharmaceutical research. 2022 May; 39(5):977-987. doi: 10.1007/s11095-022-03276-0. [PMID: 35501532]
  • Xenia Bacinschi, Adriana Mercan-Stanciu, Letitia Toma, Anca Zgura, Nicolae Bacalbasa, Chen-Peng Ifrim, Camelia Diaconu, Laura Iliescu, Radu Valeriu Toma. Glycemic Control in Patients Undergoing Treatment With Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir for Chronic Hepatitis C Infection. In vivo (Athens, Greece). 2022 May; 36(3):1438-1443. doi: 10.21873/invivo.12849. [PMID: 35478152]
  • NULL. Two new oral antivirals for covid-19: ▼molnupiravir and ▼nirmatrelvir plus ritonavir. Drug and therapeutics bulletin. 2022 05; 60(5):73-77. doi: 10.1136/dtb.2022.000008. [PMID: 35473816]
  • Heather Eng, Alyssa L Dantonio, Eugene P Kadar, R Scott Obach, Li Di, Jian Lin, Nandini C Patel, Britton Boras, Gregory S Walker, Jonathan J Novak, Emi Kimoto, Ravi Shankar P Singh, Amit S Kalgutkar. Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans. Drug metabolism and disposition: the biological fate of chemicals. 2022 05; 50(5):576-590. doi: 10.1124/dmd.121.000801. [PMID: 35153195]
  • Zhonglei Wang, Liyan Yang. In the age of Omicron variant: Paxlovid raises new hopes of COVID-19 recovery. Journal of medical virology. 2022 05; 94(5):1766-1767. doi: 10.1002/jmv.27540. [PMID: 34936106]
  • Mei Nee Chiu, Maitry Bhardwaj, Sangeeta Pilkhwal Sah. Safety profile of COVID-19 drugs in a real clinical setting. European journal of clinical pharmacology. 2022 May; 78(5):733-753. doi: 10.1007/s00228-021-03270-2. [PMID: 35088108]
  • P-H Secretan, O Thirion, V Vieillard, J Saunier, K Razazi, M Paul, B Do. Hospital compounding to face shortage: A case study of the development of a lopinavir-ritonavir oral suspension during the first wave of SARS-COV-2 in France. Annales pharmaceutiques francaises. 2022 May; 80(3):273-279. doi: 10.1016/j.pharma.2021.09.002. [PMID: 34563517]
  • Elettra Fallani, Fabio Cevenini, Pietro Enea Lazzerini, Annalisa Verdini, Simona Saponara. Off-Label Use of Hydroxychloroquine in COVID-19: Analysis of Reports of Suspected Adverse Reactions From the Italian National Network of Pharmacovigilance. Journal of clinical pharmacology. 2022 05; 62(5):646-655. doi: 10.1002/jcph.2006. [PMID: 34802170]
  • Axelle Cooreman, Anne Caufriez, Andrés Tabernilla, Raf Van Campenhout, Kaat Leroy, Prashant Kadam, Julen Sanz Serrano, Bruna Dos Santos Rodrigues, Pieter Annaert, Mathieu Vinken. Effects of Drugs Formerly Proposed for COVID-19 Treatment on Connexin43 Hemichannels. International journal of molecular sciences. 2022 Apr; 23(9):. doi: 10.3390/ijms23095018. [PMID: 35563409]
  • Andy Extance. Covid-19: What is the evidence for the antiviral Paxlovid?. BMJ (Clinical research ed.). 2022 04; 377(?):o1037. doi: 10.1136/bmj.o1037. [PMID: 35477536]
  • Katy Moore, Nilay Thakkar, Mindy Magee, Heather Sevinsky, Blisse Vakkalagadda, Susan Lubin, Cyril Llamoso, Peter Ackerman. Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants. Antimicrobial agents and chemotherapy. 2022 04; 66(4):e0225121. doi: 10.1128/aac.02251-21. [PMID: 35315687]
  • NULL. COVID-19 updates: FDA restricts use of sotrovimab. The Medical letter on drugs and therapeutics. 2022 04; 64(1648):64. doi: NULL. [PMID: 35436778]
  • Laura Waters, Fiona Marra, Anton Pozniak, James Cockburn, Marta Boffito. Ritonavir and COVID-19: pragmatic guidance is important. Lancet (London, England). 2022 04; 399(10334):1464-1465. doi: 10.1016/s0140-6736(22)00280-x. [PMID: 35334211]
  • Gerd Mikus, Kathrin I Foerster, Theresa Terstegen, Cathrin Vogt, André Said, Martin Schulz, Walter E Haefeli. Oral Drugs Against COVID-19. Deutsches Arzteblatt international. 2022 Apr; 119(15):263-269. doi: 10.3238/arztebl.m2022.0152. [PMID: 35302484]
  • Jennifer Hammond, Heidi Leister-Tebbe, Annie Gardner, Paula Abreu, Weihang Bao, Wayne Wisemandle, MaryLynn Baniecki, Victoria M Hendrick, Bharat Damle, Abraham Simón-Campos, Rienk Pypstra, James M Rusnak. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. The New England journal of medicine. 2022 04; 386(15):1397-1408. doi: 10.1056/nejmoa2118542. [PMID: 35172054]
  • L Lanthier, M-É Plourde, M Cauchon. [In symptomatic, nonhospitalized unvaccinated adults with mild to moderate COVID-19 at risk for progression to severe disease, does nirmatrelvir/ritonavir decrease the risk of COVID-19-related hospitalization or all-cause mortality while being safe?]. La Revue de medecine interne. 2022 04; 43(4):270-271. doi: 10.1016/j.revmed.2022.02.008. [PMID: 35279350]
  • Á Estella, J L Garcia Garmendia, C de la Fuente, J F Machado Casas, M E Yuste, R Amaya Villar, M A Estecha, L Yaguez Mateos, M L Cantón Bulnes, A Loza, J Mora, L Fernández Ruiz, B Díez Del Corral Fernández, M Rojas Amezcua, M I Rodriguez Higueras, I Díaz Torres, M Recuerda Núñez, M Zaheri Beryanaki, F Rivera Espinar, D F Matallana Zapata, S G Moreno Cano, B Gimenez Beltrán, N Muñoz, A Sainz de Baranda Piñero, P Bustelo Bueno, E Moreno Barriga, J J Rios Toro, M Pérez Ruiz, C Gómez González, A Breval Flores, A de San José Bermejo Gómez, M A Ruiz Cabello Jimenez, M Guerrero Marín, A Ortega Ordiales, J Tejero-Aranguren, C Rodriguez Mejías, J Gomez de Oña, C de la Hoz, D Ocaña Fernández, S Ibañez Cuadros, J Garnacho Montero. Predictive factors of six-week mortality in critically ill patients with SARS-CoV-2: A multicenter prospective study. Medicina intensiva. 2022 04; 46(4):179-191. doi: 10.1016/j.medine.2021.02.008. [PMID: 35461665]
  • Yvette N Lamb. Nirmatrelvir Plus Ritonavir: First Approval. Drugs. 2022 Apr; 82(5):585-591. doi: 10.1007/s40265-022-01692-5. [PMID: 35305258]
  • Heidi Ledford, Amy Maxmen. African clinical trial denied access to key COVID drug Paxlovid. Nature. 2022 04; 604(7906):412-413. doi: 10.1038/d41586-022-00919-5. [PMID: 35379975]
  • Steven Fishbane, Jamie S Hirsch, Vinay Nair. Special Considerations for Paxlovid Treatment Among Transplant Recipients With SARS-CoV-2 Infection. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2022 04; 79(4):480-482. doi: 10.1053/j.ajkd.2022.01.001. [PMID: 35032591]
  • Miao Yu, Deng-Chao Wang, Sheng Li, Yue-Hua Lei, Jian Wei, Li-Yan Huang. Meta-analysis of arbidol versus lopinavir/ritonavir in the treatment of coronavirus disease 2019. Journal of medical virology. 2022 04; 94(4):1513-1522. doi: 10.1002/jmv.27481. [PMID: 34837230]
  • René J Boosman, Cornedine J de Gooijer, Stefanie L Groenland, Jacobus A Burgers, Paul Baas, Vincent van der Noort, Jos H Beijnen, Alwin D R Huitema, Neeltje Steeghs. Ritonavir-Boosted Exposure of Kinase Inhibitors: an Open Label, Cross-over Pharmacokinetic Proof-of-Concept Trial with Erlotinib. Pharmaceutical research. 2022 Apr; 39(4):669-676. doi: 10.1007/s11095-022-03244-8. [PMID: 35352280]
  • Rahman Abdizadeh, Farzin Hadizadeh, Tooba Abdizadeh. In silico analysis and identification of antiviral coumarin derivatives against 3-chymotrypsin-like main protease of the novel coronavirus SARS-CoV-2. Molecular diversity. 2022 Apr; 26(2):1053-1076. doi: 10.1007/s11030-021-10230-6. [PMID: 34213728]
  • Yuna Sadaka, Midori Soda, Akiyo Hori, Yuri Miyahara, Yasuhisa Oida, Yoichi Nishigaki, Eiichi Tomita, Takashi Mizui, Kiyoyuki Kitaichi. Combined Use of Calcium-channel Blockers With Ombitasvir/Paritaprevir/Ritonavir Exacerbates Peripheral Edema in Elderly Japanese Patients. Anticancer research. 2022 04; 42(4):2087-2093. doi: 10.21873/anticanres.15690. [PMID: 35347032]
  • Srinivas Reddy Jitta, Navya Ajitkumar Bhaskaran, Salwa, Lalit Kumar. Anti-oxidant Containing Nanostructured Lipid Carriers of Ritonavir: Development, Optimization, and In Vitro and In Vivo Evaluations. AAPS PharmSciTech. 2022 Mar; 23(4):88. doi: 10.1208/s12249-022-02240-w. [PMID: 35296970]
  • Emily G McDonald, Todd C Lee. Title Not Available. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2022 03; 194(9):E365-E366. doi: 10.1503/cmaj.220081-f. [PMID: 35256399]
  • Ariel Izcovich, Reed Alexander Siemieniuk, Jessica Julia Bartoszko, Long Ge, Dena Zeraatkar, Elena Kum, Anila Qasim, Assem M Khamis, Bram Rochwerg, Thomas Agoritsas, Derek K Chu, Shelley L McLeod, Reem A Mustafa, Per Vandvik, Romina Brignardello-Petersen. Adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomised trials. BMJ open. 2022 03; 12(3):e048502. doi: 10.1136/bmjopen-2020-048502. [PMID: 35236729]
  • Milad Bagheri, Ahmadreza Niavarani. Molecular dynamics analysis predicts ritonavir and naloxegol strongly block the SARS-CoV-2 spike protein-hACE2 binding. Journal of biomolecular structure & dynamics. 2022 03; 40(4):1597-1606. doi: 10.1080/07391102.2020.1830854. [PMID: 33030105]
  • N R Catlin, C J Bowman, S N Campion, J R Cheung, W S Nowland, J G Sathish, C M Stethem, L Updyke, G D Cappon. Reproductive and developmental safety of nirmatrelvir (PF-07321332), an oral SARS-CoV-2 Mpro inhibitor in animal models. Reproductive toxicology (Elmsford, N.Y.). 2022 03; 108(?):56-61. doi: 10.1016/j.reprotox.2022.01.006. [PMID: 35101563]
  • Maiara Camotti Montanha, Francesc Fabrega, Alice Howarth, Nicolas Cottura, Hannah Kinvig, Fazila Bunglawala, Andrew Lloyd, Paolo Denti, Catriona Waitt, Marco Siccardi. Predicting Drug-Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling. Clinical pharmacokinetics. 2022 03; 61(3):375-386. doi: 10.1007/s40262-021-01067-1. [PMID: 34635995]
  • Heidi Ledford. Hundreds of COVID trials could provide a deluge of new drugs. Nature. 2022 03; 603(7899):25-27. doi: 10.1038/d41586-022-00562-0. [PMID: 35233098]
  • Felix Stader, Manuel Battegay, Parham Sendi, Catia Marzolini. Physiologically Based Pharmacokinetic Modelling to Investigate the Impact of the Cytokine Storm on CYP3A Drug Pharmacokinetics in COVID-19 Patients. Clinical pharmacology and therapeutics. 2022 03; 111(3):579-584. doi: 10.1002/cpt.2402. [PMID: 34496043]
  • Pinky Kotecha, Alexander Light, Enrico Checcucci, Daniele Amparore, Cristian Fiori, Francesco Porpiglia, Prokar Dasgupta, Oussama Elhage. Repurposing of drugs for COVID-19: a systematic review and meta-analysis. Panminerva medica. 2022 Mar; 64(1):96-114. doi: 10.23736/s0031-0808.20.04024-0. [PMID: 33073552]
  • A Oyefabi, S Musa, H Kambai, I Usman, J Gwamna, J Sheyin, O Ige, M Abdullahi, J Sunday, H N Kera, A Atiku, H Dauda, G C Umeh, T Olasinde, A Abdullahi. Comparison of the Ivermectin and Lopinavir/Ritonavir Treatment Outcomes among COVID-19 Mild to Moderate Cases in Kaduna State. West African journal of medicine. 2022 Feb; 39(2):140-146. doi: NULL. [PMID: 35278050]
  • Ann Danaiya Usher. The global COVID-19 treatment divide. Lancet (London, England). 2022 02; 399(10327):779-782. doi: 10.1016/s0140-6736(22)00372-5. [PMID: 35219388]
  • Eric J Rubin, Lindsey R Baden, Stephen Morrissey. Audio Interview: A New Antiviral against Covid-19. The New England journal of medicine. 2022 02; 386(7):e25. doi: 10.1056/nejme2202349. [PMID: 35172062]
  • Rajesh T Gandhi, Preeti N Malani, Carlos Del Rio. COVID-19 Therapeutics for Nonhospitalized Patients. JAMA. 2022 02; 327(7):617-618. doi: 10.1001/jama.2022.0335. [PMID: 35029659]
  • Emily G McDonald, Todd C Lee. Nirmatrelvir-ritonavir for COVID-19. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2022 02; 194(6):E218. doi: 10.1503/cmaj.220081. [PMID: 35115376]
  • NULL. Treatment of COVID-19 in high-risk outpatients. The Medical letter on drugs and therapeutics. 2022 Feb; 64(1643):e1. doi: NULL. [PMID: 35134051]
  • Serdar Durdagi, Muge Didem Orhan, Busecan Aksoydan, Seyma Calis, Berna Dogan, Kader Sahin, Aida Shahraki, Necla Birgül Iyison, Timucin Avsar. Screening of Clinically Approved and Investigation Drugs as Potential Inhibitors of SARS-CoV-2: A Combined in silico and in vitro Study. Molecular informatics. 2022 02; 41(2):e2100062. doi: 10.1002/minf.202100062. [PMID: 34529322]
  • Awadhesh Kumar Singh, Akriti Singh, Ritu Singh, Anoop Misra. An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19. Diabetes & metabolic syndrome. 2022 Feb; 16(2):102396. doi: 10.1016/j.dsx.2022.102396. [PMID: 35051686]
  • Manisha Choudhury, Anantha K Dhanabalan, Nabajyoti Goswami. Understanding the binding mechanism for potential inhibition of SARS-CoV-2 Mpro and exploring the modes of ACE2 inhibition by hydroxychloroquine. Journal of cellular biochemistry. 2022 02; 123(2):347-358. doi: 10.1002/jcb.30174. [PMID: 34741481]
  • Caroline E Dunk, Lena Serghides. Protease inhibitor-based antiretroviral therapy in pregnancy: effects on hormones, placenta, and decidua. The lancet. HIV. 2022 02; 9(2):e120-e129. doi: 10.1016/s2352-3018(21)00249-6. [PMID: 34863352]
  • Giusy Tiseo, Dafna Yahav, Mical Paul, Marco Tinelli, Gaetan Gavazzi, Cristina Mussini, Virginie Prendki, Marco Falcone. What have we learned from the first to the second wave of COVID-19 pandemic? An international survey from the ESCMID Study Group for Infection in the Elderly (ESGIE) group. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 2022 Feb; 41(2):281-288. doi: 10.1007/s10096-021-04377-1. [PMID: 34775534]
  • NULL. Paxlovid for treatment of COVID-19. The Medical letter on drugs and therapeutics. 2022 01; 64(1642):9-10. doi: NULL. [PMID: 35134040]
  • Luciana L Borio, Rick A Bright, Ezekiel J Emanuel. A National Strategy for COVID-19 Medical Countermeasures: Vaccines and Therapeutics. JAMA. 2022 Jan; 327(3):215-216. doi: 10.1001/jama.2021.24165. [PMID: 34989782]